b'<?xml version="1.0" encoding="utf-8"?>\n<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">\n<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">\n    \n    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />\n        <!-- AppResources meta begin -->\n        <script type="text/javascript">var ncbi_startTime = new Date();</script>\n        <!-- AppResources meta end -->\n        \n        <!-- TemplateResources meta begin -->\n        <meta name="paf_template" content="" />\n\n        <!-- TemplateResources meta end -->\n        \n        <!-- Logger begin -->\n        <meta name="ncbi_db" content="pmc" /><meta name="ncbi_pdid" content="article" /><meta name="ncbi_acc" content="" /><meta name="ncbi_domain" content="phenaturepg" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/articles/PMC1232869/" /><meta name="ncbi_app" content="pmc" />\n        <!-- Logger end -->\n        \n        <title>Chloroquine is a potent inhibitor of SARS coronavirus infection and spread</title>\n        \n        <!-- AppResources external_resources begin -->\n        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>\n\n        <!-- AppResources external_resources end -->\n        \n        <!-- Page meta begin -->\n        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1232869/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="Virology Journal" /><meta name="citation_title" content="Chloroquine is a potent inhibitor of SARS coronavirus infection and spread" /><meta name="citation_authors" content="Martin J Vincent, Eric Bergeron, Suzanne Benjannet, Bobbie R Erickson, Pierre E Rollin, Thomas G Ksiazek, Nabil G Seidah, Stuart T Nichol" /><meta name="citation_date" content="2005" /><meta name="citation_volume" content="2" /><meta name="citation_doi" content="10.1186/1743-422X-2-69" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC1232869/?report=abstract" /><meta name="citation_pmid" content="16115318" /><meta name="DC.Title" content="Chloroquine is a potent inhibitor of SARS coronavirus infection and spread" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="Nature Publishing Group" /><meta name="DC.Contributor" content="Martin J Vincent" /><meta name="DC.Contributor" content="Eric Bergeron" /><meta name="DC.Contributor" content="Suzanne Benjannet" /><meta name="DC.Contributor" content="Bobbie R Erickson" /><meta name="DC.Contributor" content="Pierre E Rollin" /><meta name="DC.Contributor" content="Thomas G Ksiazek" /><meta name="DC.Contributor" content="Nabil G Seidah" /><meta name="DC.Contributor" content="Stuart T Nichol" /><meta name="DC.Date" content="2005" /><meta name="DC.Identifier" content="10.1186/1743-422X-2-69" /><meta name="DC.Language" content="en" /><meta property="og:title" content="Chloroquine is a potent inhibitor of SARS coronavirus infection and spread" /><meta property="og:type" content="article" /><meta property="og:description" content="Severe acute respiratory syndrome (SARS) is caused by a newly discovered coronavirus (SARS-CoV). No effective prophylactic or post-exposure therapy is currently available.We report, however, that chloroquine has strong antiviral effects on SARS-CoV infection ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1232869/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbi" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc_extras_prnt.min.css" type="text/css" media="print" /><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:\'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/\'" /><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css" /><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-phenaturepg.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">\n        div.pmc_para_cit li.highlight,\n        div.pmc_para_cit li.highlight .one_line_source\n        { background: #E0E0E0; }\n        a.bibr.highlight { background: #E0E0E0; } \n      </style><meta name="cited_in_systematic_reviews" content="" /><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC1232869/epub/" /><link rel="alternate" type="application/pdf" href="/pmc/articles/PMC1232869/pdf/12985_2005_Article_84.pdf" />\n\n        <!-- Page meta end -->\n    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="8A1B33DDE99A3E9100000000042A042A.m_8" />\n<meta name=\'referrer\' content=\'origin-when-cross-origin\'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print" /></head>\n    <body class="article">\n        <div class="grid">\n            <div class="col twelve_col nomargin shadow">\n                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->\n                <div class="sysmessages">\n                    <noscript>\n\t<p class="nojs">\n\t<strong>Warning:</strong>\n\tThe NCBI web site requires JavaScript to function. \n\t<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>\n\t</p>\n\t</noscript>\n                </div>\n                <!--/.sysmessage-->\n                <div class="wrap">\n                    <div class="page">\n                        <div class="top">\n                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main\n                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to\n                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>\n                            <div class="header">\n    <div class="res_logo">\n  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>\n  <div class="NLMLogo">\n    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>\n    <br />\n    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>\n  </div>\n</div>\n    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" class="last" data-ac_dict="pmc-search-autocomplete">PMC</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:\'pmc-search-autocomplete\',disableUrl:\'NcbiSearchBarAutoComplCtrl\'" autocomplete="off" data-sbconfig="ds:\'no\',pjs:\'no\',afs:\'yes\'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>\n                        <a href="/pmc/advanced/">Advanced</a>\n                    </li><li>\n                        <a href="/pmc/journals/">Journal list</a>\n                    </li><li class="help">\n                        <a target="_blank" href="/books/NBK3825/">Help</a>\n                    </li></ul></div>\n</div>\n\n                            \n                            \n                        <!--<component id="Page" label="headcontent"/>-->\n                            \n                        </div>\n                        <div class="content">\n                            <!-- site messages -->\n                            <div class="container">\n    <div id="maincontent" class="content eight_col col">\n        <div class="navlink-box">\n            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="article-entrez-filter"><a href="/pmc/?term=Nature%20Public%20Health%20Emergency%20Collection[filter]" class="navlink">Nature Public Health Emergency Collection</a></li><li class="accid">PMC1232869</li></ul>\n        </div>\n\n        <!-- Journal banner -->\n        <div class="pmc-page-banner whole_rhythm"><div class="banner-generic-logo-background inline_block"><div class="banner-journal-publisher-over-image"><div class="banner-journal-name bl-jtitle-phenaturepg">Virology Journal</div><div class="banner-publisher-name">Nature Publishing Group</div></div></div></div>\n        \n        <!--component id=\'MainPortlet\' label=\'search-reference\'/-->\n        \n        <!-- Book content -->\n        <div class="">\n            \n        \n            \n            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: [\'h2\'], headingExclude: \':hidden\'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="inline_block eight_col va_top"><div><div><span class="cit"><span id="pmcmata">Virol J</span>. 2005; 2: 69. </span></div><div><span class="fm-vol-iss-date">Published online 2005 Aug 22. </span>  <span class="doi">doi:\xc2\xa0<a href="//dx.doi.org/10.1186%2F1743-422X-2-69" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1186/1743-422X-2-69</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC1232869</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/16115318">16115318</a></div></div></div></div><h1 class="content-title">Chloroquine is a potent inhibitor of SARS coronavirus infection and spread</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Vincent%20MJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16115318" class="affpopup" co-rid="_co_idm140144751622272" co-class="co-affbox">Martin J Vincent</a>,<sup>1</sup> <a href="/pubmed/?term=Bergeron%20E%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16115318" class="affpopup" co-rid="_co_idm140144750927600" co-class="co-affbox">Eric Bergeron</a>,<sup>2</sup> <a href="/pubmed/?term=Benjannet%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16115318" class="affpopup" co-rid="_co_idm140144751619264" co-class="co-affbox">Suzanne Benjannet</a>,<sup>2</sup> <a href="/pubmed/?term=Erickson%20BR%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16115318" class="affpopup" co-rid="_co_idm140144820403440" co-class="co-affbox">Bobbie R Erickson</a>,<sup>1</sup> <a href="/pubmed/?term=Rollin%20PE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16115318" class="affpopup" co-rid="_co_idm140144820401296" co-class="co-affbox">Pierre E Rollin</a>,<sup>1</sup> <a href="/pubmed/?term=Ksiazek%20TG%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16115318" class="affpopup" co-rid="_co_idm140144743098368" co-class="co-affbox">Thomas G Ksiazek</a>,<sup>1</sup> <a href="/pubmed/?term=Seidah%20NG%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16115318" class="affpopup" co-rid="_co_idm140144743096000" co-class="co-affbox">Nabil G Seidah</a>,<sup>2</sup> and  <a href="/pubmed/?term=Nichol%20ST%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16115318" class="affpopup" co-rid="_co_idm140144747367152" co-class="co-affbox">Stuart T Nichol</a><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup><sup>1</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm140144751622272"><h3 class="no_margin">Martin J Vincent</h3><p><sup>1</sup>Special Pathogens Brach, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 1600 Clifton Road, 30333 USA </p><div>Find articles by <a href="/pubmed/?term=Vincent%20MJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16115318">Martin J Vincent</a></div></div><div id="_co_idm140144750927600"><h3 class="no_margin">Eric Bergeron</h3><p><sup>2</sup>Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, Montreal, 110 Pine Ave West, QCH2W1R7 Canada </p><div>Find articles by <a href="/pubmed/?term=Bergeron%20E%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16115318">Eric Bergeron</a></div></div><div id="_co_idm140144751619264"><h3 class="no_margin">Suzanne Benjannet</h3><p><sup>2</sup>Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, Montreal, 110 Pine Ave West, QCH2W1R7 Canada </p><div>Find articles by <a href="/pubmed/?term=Benjannet%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16115318">Suzanne Benjannet</a></div></div><div id="_co_idm140144820403440"><h3 class="no_margin">Bobbie R Erickson</h3><p><sup>1</sup>Special Pathogens Brach, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 1600 Clifton Road, 30333 USA </p><div>Find articles by <a href="/pubmed/?term=Erickson%20BR%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16115318">Bobbie R Erickson</a></div></div><div id="_co_idm140144820401296"><h3 class="no_margin">Pierre E Rollin</h3><p><sup>1</sup>Special Pathogens Brach, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 1600 Clifton Road, 30333 USA </p><div>Find articles by <a href="/pubmed/?term=Rollin%20PE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16115318">Pierre E Rollin</a></div></div><div id="_co_idm140144743098368"><h3 class="no_margin">Thomas G Ksiazek</h3><p><sup>1</sup>Special Pathogens Brach, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 1600 Clifton Road, 30333 USA </p><div>Find articles by <a href="/pubmed/?term=Ksiazek%20TG%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16115318">Thomas G Ksiazek</a></div></div><div id="_co_idm140144743096000"><h3 class="no_margin">Nabil G Seidah</h3><p><sup>2</sup>Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, Montreal, 110 Pine Ave West, QCH2W1R7 Canada </p><div>Find articles by <a href="/pubmed/?term=Seidah%20NG%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16115318">Nabil G Seidah</a></div></div><div id="_co_idm140144747367152"><h3 class="no_margin">Stuart T Nichol</h3><p><sup>1</sup>Special Pathogens Brach, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 1600 Clifton Road, 30333 USA </p><div>Find articles by <a href="/pubmed/?term=Nichol%20ST%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16115318">Stuart T Nichol</a></div></div></div></div><div class="fm-panel half_rhythm"><div class="togglers"><a href="#" class="pmctoggle" rid="idm140144741697712_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140144741697712_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm140144741697712_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-authors-info fm-panel hide half_rhythm" id="idm140144741697712_ai" style="display:none"><div class="fm-affl" lang="en" id="Aff1"><sup>1</sup>Special Pathogens Brach, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 1600 Clifton Road, 30333 USA </div><div class="fm-affl" lang="en" id="Aff2"><sup>2</sup>Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, Montreal, 110 Pine Ave West, QCH2W1R7 Canada </div><div><span class="fm-affl">Martin J Vincent, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.cdc@tnecnivm" class="oemail">vog.cdc@tnecnivm</a></span>.</div><div><a href="#idm140144741697712aff-info">Contributor Information</a>.</div><div><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup>Corresponding author.</div></div><div class="fm-article-notes fm-panel hide half_rhythm" id="idm140144741697712_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2005 Jul 12; Accepted 2005 Aug 22.</div></div><div class="permissions fm-panel half_rhythm hide" id="idm140144741697712_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a> &#x000a9; Vincent et al; licensee BioMed Central Ltd. 2005</div><div class="license half_rhythm">This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="fm-panel"><div>This article has been <a href="/pmc/articles/PMC1232869/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="Abs1" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="Abs1title">Abstract</h2><!--article-meta--><div><div id="idm140144744373616" class="sec sec-first"><h3 id="idm140144744373616title">Background</h3><p id="idm140144744373232" class="p p-first-last">Severe acute respiratory syndrome (SARS) is caused by a newly discovered coronavirus (SARS-CoV). No effective prophylactic or post-exposure therapy is currently available.</p></div><div id="idm140144744372784" class="sec"><h3 id="idm140144744372784title">Results</h3><p id="idm140144744372400" class="p p-first-last">We report, however, that chloroquine has strong antiviral effects on SARS-CoV infection of primate cells. These inhibitory effects are observed when the cells are treated with the drug either before or after exposure to the virus, suggesting both prophylactic and therapeutic advantage. In addition to the well-known functions of chloroquine such as elevations of endosomal pH, the drug appears to interfere with terminal glycosylation of the cellular receptor, angiotensin-converting enzyme 2. This may negatively influence the virus-receptor binding and abrogate the infection, with further ramifications by the elevation of vesicular pH, resulting in the inhibition of infection and spread of SARS CoV at clinically admissible concentrations.</p></div><div id="idm140144746626736" class="sec"><h3 id="idm140144746626736title">Conclusion</h3><p id="idm140144746626352" class="p p-first-last">Chloroquine is effective in preventing the spread of SARS CoV in cell culture. Favorable inhibition of virus spread was observed when the cells were either treated with chloroquine prior to or after SARS CoV infection. In addition, the indirect immunofluorescence assay described herein represents a simple and rapid method for screening SARS-CoV antiviral compounds.</p></div><div id="idm140144746625712" class="sec sec-last"><h3 id="idm140144746625712title">Electronic supplementary material</h3><p id="idm140144746625328" class="p p-first-last">The online version of this article (doi:10.1186/1743-422X-2-69) contains supplementary material, which is available to authorized users.</p></div></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">severe acute respiratory syndrome coronavirus, chloroquine, inhibition, therapy</span></div></div><div id="Sec1" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec1title">Background</h2><p id="idm140144747063104" class="p p-first">Severe acute respiratory syndrome (SARS) is an emerging disease that was first reported in Guangdong Province, China, in late 2002. The disease rapidly spread to at least 30 countries within months of its first appearance, and concerted worldwide efforts led to the identification of the etiological agent as SARS coronavirus (SARS-CoV), a novel member of the family <em>Coronaviridae</em> [<a href="#CR1" rid="CR1" class=" bibr popnode">1</a>]. Complete genome sequencing of SARS-CoV [<a href="#CR2" rid="CR2" class=" bibr popnode">2</a>, <a href="#CR3" rid="CR3" class=" bibr popnode">3</a>] confirmed that this pathogen is not closely related to any of the previously established coronavirus groups. Budding of the SARS-CoV occurs in the Golgi apparatus [<a href="#CR4" rid="CR4" class=" bibr popnode">4</a>] and results in the incorporation of the envelope spike glycoprotein into the virion. The spike glycoprotein is a type I membrane protein that facilitates viral attachment to the cellular receptor and initiation of infection, and angiotensin-converting enzyme-2 (ACE2) has been identified as a functional cellular receptor of SARS-CoV [<a href="#CR5" rid="CR5" class=" bibr popnode">5</a>]. We have recently shown that the processing of the spike protein was effected by furin-like convertases and that inhibition of this cleavage by a specific inhibitor abrogated cytopathicity and significantly reduced the virus titer of SARS-CoV [<a href="#CR6" rid="CR6" class=" bibr popnode">6</a>].</p><p id="idm140144744754336" class="p p-last">Due to the severity of SARS-CoV infection, the potential for rapid spread of the disease, and the absence of proven effective and safe <em>in vivo</em> inhibitors of the virus, it is important to identify drugs that can effectively be used to treat or prevent potential SARS-CoV infections. Many novel therapeutic approaches have been evaluated in laboratory studies of SARS-CoV: notable among these approaches are those using siRNA [<a href="#CR7" rid="CR7" class=" bibr popnode">7</a>], passive antibody transfer [<a href="#CR8" rid="CR8" class=" bibr popnode">8</a>], DNA vaccination [<a href="#CR9" rid="CR9" class=" bibr popnode">9</a>], vaccinia or parainfluenza virus expressing the spike protein [<a href="#CR10" rid="CR10" class=" bibr popnode">10</a>, <a href="#CR11" rid="CR11" class=" bibr popnode">11</a>], interferons [<a href="#CR12" rid="CR12" class=" bibr popnode">12</a>, <a href="#CR13" rid="CR13" class=" bibr popnode">13</a>], and monoclonal antibody to the S1-subunit of the spike glycoprotein that blocks receptor binding [<a href="#CR14" rid="CR14" class=" bibr popnode">14</a>]. In this report, we describe the identification of chloroquine as an effective pre- and post-infection antiviral agent for SARS-CoV. Chloroquine, a 9-aminoquinoline that was identified in 1934, is a weak base that increases the pH of acidic vesicles. When added extracellularly, the non-protonated portion of chloroquine enters the cell, where it becomes protonated and concentrated in acidic, low-pH organelles, such as endosomes, Golgi vesicles, and lysosomes. Chloroquine can affect virus infection in many ways, and the antiviral effect depends in part on the extent to which the virus utilizes endosomes for entry. Chloroquine has been widely used to treat human diseases, such as malaria, amoebiosis, HIV, and autoimmune diseases, without significant detrimental side effects [<a href="#CR15" rid="CR15" class=" bibr popnode">15</a>]. Together with data presented here, showing virus inhibition in cell culture by chloroquine doses compatible with patient treatment, these features suggest that further evaluation of chloroquine in animal models of SARS-CoV infection would be warranted as we progress toward finding effective antivirals for prevention or treatment of the disease.</p></div><div id="Sec2" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec2title">Results</h2><div id="Sec3" class="sec sec-first"><h3 id="Sec3title">Preinfection chloroquine treatment renders Vero E6 cells refractory to SARS-CoV infection</h3><p id="idm140144741761584" class="p p-first-last">In order to investigate if chloroquine might prevent SARS-CoV infection, permissive Vero E6 cells [<a href="#CR1" rid="CR1" class=" bibr popnode">1</a>] were pretreated with various concentrations of chloroquine (0.1&#x02013;10 &#x003bc;M) for 20&#x02013;24 h prior to virus infection. Cells were then infected with SARS-CoV, and virus antigens were visualized by indirect immunofluorescence as described in Materials and Methods. Microscopic examination (Fig. <a href="/pmc/articles/PMC1232869/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">(Fig.1A)</span></span><span>1A</span></a>) of the control cells (untreated, infected) revealed extensive SARS-CoV-specific immunostaining of the monolayer. A dose-dependant decrease in virus antigen-positive cells was observed starting at 0.1 &#x003bc;M chloroquine, and concentrations of 10 &#x003bc;M completely abolished SARS-CoV infection. For quantitative purposes, we counted the number of cells stained positive from three random locations on a slide. The average number of positively stained control cells was scored as 100% and was compared with the number of positive cells observed under various chloroquine concentrations (Fig. <a href="/pmc/articles/PMC1232869/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">(Fig.1B).</span></span><span>1B</span></a>). Pretreatment with 0.1, 1, and 10 &#x003bc;M chloroquine reduced infectivity by 28%, 53%, and 100%, respectively. Reproducible results were obtained from three independent experiments. These data demonstrated that pretreatment of Vero E6 cells with chloroquine rendered these cells refractory to SARS-CoV infection.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="Fig1" co-legend-rid="lgnd_Fig1"><a href="/pmc/articles/PMC1232869/figure/Fig1/" target="figure" rid-figpopup="Fig1" rid-ob="ob-Fig1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140144818573712" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12985_2005_Article_84_Fig1_HTML.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is 12985_2005_Article_84_Fig1_HTML.jpg" src="/pmc/articles/PMC1232869/bin/12985_2005_Article_84_Fig1_HTML.jpg" /></div><div id="largeobj_idm140144818573712" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC1232869/figure/Fig1/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig1"><div><a class="figpopup" href="/pmc/articles/PMC1232869/figure/Fig1/" target="figure" rid-figpopup="Fig1" rid-ob="ob-Fig1">Figure 1</a></div><!--caption a7--><div class="caption"><p id="idm140144749089312"><strong>Prophylactic effect of chloroquine</strong>. Vero E6 cells pre-treated with chloroquine for 20 hrs. Chloroquine-containing media were removed and the cells were washed with phosphate buffered saline before they were infected with SARS-CoV (0.5 multiplicity of infection) for 1 h. in the absence of chloroquine. Virus was then removed and the cells were maintained in Opti-MEM (Invitrogen) for 16&#x02013;18 h in the absence of chloroquine. SARS-CoV antigens were stained with virus-specific HMAF, followed by FITC-conjugated secondary antibodies. <strong>(A)</strong> The concentration of chloroquine used is indicated on the top of each panel. <strong>(B)</strong> SARS-CoV antigen-positive cells at three random locations were captured by using a digital camera, the number of antigen-positive cells was determined, and the average inhibition was calculated. Percent inhibition was obtained by considering the untreated control as 0% inhibition. The vertical bars represent the range of SEM.</p></div></div></div></div><div id="Sec4" class="sec"><h3 id="Sec4title">Postinfection chloroquine treatment is effective in preventing the spread of SARS-CoV infection</h3><p id="idm140144818571888" class="p p-first">In order to investigate the antiviral properties of chloroquine on SARS-CoV after the initiation of infection, Vero E6 cells were infected with the virus and fresh medium supplemented with various concentrations of chloroquine was added immediately after virus adsorption. Infected cells were incubated for an additional 16&#x02013;18 h, after which the presence of virus antigens was analyzed by indirect immunofluorescence analysis. When chloroquine was added after the initiation of infection, there was a dramatic dose-dependant decrease in the number of virus antigen-positive cells (Fig. <a href="/pmc/articles/PMC1232869/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">(Fig.2A).</span></span><span>2A</span></a>). As little as 0.1&#x02013;1 &#x003bc;M chloroquine reduced the infection by 50% and up to 90&#x02013;94% inhibition was observed with 33&#x02013;100 &#x003bc;M concentrations (Fig. <a href="/pmc/articles/PMC1232869/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">(Fig.2B).</span></span><span>2B</span></a>). At concentrations of chloroquine in excess of 1 &#x003bc;M, only a small number of individual cells were initially infected, and the spread of the infection to adjacent cells was all but eliminated. A half-maximal inhibitory effect was estimated to occur at 4.4 &#x000b1; 1.0 &#x003bc;M chloroquine (Fig. <a href="/pmc/articles/PMC1232869/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">(Fig.2C).</span></span><span>2C</span></a>). These data clearly show that addition of chloroquine can effectively reduce the establishment of infection and spread of SARS-CoV if the drug is added immediately following virus adsorption.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="Fig2" co-legend-rid="lgnd_Fig2"><a href="/pmc/articles/PMC1232869/figure/Fig2/" target="figure" rid-figpopup="Fig2" rid-ob="ob-Fig2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140144821321728" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12985_2005_Article_84_Fig2_HTML.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is 12985_2005_Article_84_Fig2_HTML.jpg" src="/pmc/articles/PMC1232869/bin/12985_2005_Article_84_Fig2_HTML.jpg" /></div><div id="largeobj_idm140144821321728" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC1232869/figure/Fig2/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig2"><div><a class="figpopup" href="/pmc/articles/PMC1232869/figure/Fig2/" target="figure" rid-figpopup="Fig2" rid-ob="ob-Fig2">Figure 2</a></div><!--caption a7--><div class="caption"><p id="idm140144821324176"><strong>Post-infection chloroquine treatment reduces SARS-CoV infection and spread</strong>. Vero E6 cells were seeded and infected as described for Fig. 1 except that chloroquine was added only after virus adsorption. Cells were maintained in Opti-MEM (Invitrogen) containing chloroquine for 16&#x02013;18 h, after which they were processed for immunofluorescence. <strong>(A)</strong> The concentration of chloroquine is indicated on the top. <strong>(B)</strong> Percent inhibition and SEM were calculated as in Fig. 1B. <strong>(C)</strong> The effective dose (ED<sub>50</sub>) was calculated using commercially available software (Grafit, version 4, Erithacus Software).</p></div></div></div><p id="idm140144821320640" class="p p-last">Electron microscopic analysis indicated the appearance of significant amounts of extracellular virus particles 5&#x02013;6 h after infection [<a href="#CR16" rid="CR16" class=" bibr popnode">16</a>]. Since we observed antiviral effects by chloroquine immediately after virus adsorption, we further extended the analysis by adding chloroquine 3 and 5 h after virus adsorption and examined for the presence of virus antigens after 20 h. We found that chloroquine was still significantly effective even when added 5 h after infection (Fig. <a href="/pmc/articles/PMC1232869/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">(Fig.3);</span></span><span>3</span></a>); however, to obtain equivalent antiviral effect, a higher concentration of chloroquine was required if the drug was added 3 or 5 h after adsorption.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="Fig3" co-legend-rid="lgnd_Fig3"><a href="/pmc/articles/PMC1232869/figure/Fig3/" target="figure" rid-figpopup="Fig3" rid-ob="ob-Fig3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140144820570336" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12985_2005_Article_84_Fig3_HTML.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is 12985_2005_Article_84_Fig3_HTML.jpg" src="/pmc/articles/PMC1232869/bin/12985_2005_Article_84_Fig3_HTML.jpg" /></div><div id="largeobj_idm140144820570336" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC1232869/figure/Fig3/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig3"><div><a class="figpopup" href="/pmc/articles/PMC1232869/figure/Fig3/" target="figure" rid-figpopup="Fig3" rid-ob="ob-Fig3">Figure 3</a></div><!--caption a7--><div class="caption"><p id="idm140144820571056"><strong>Timed post-infection treatment with chloroquine</strong>. This experiment is similar to that depicted in Fig. 2 except that cells were infected at 1 multiplicity of infection, and chloroquine (10, 25, and 50 &#x003bc;M) was added 3 or 5 h after infection.</p></div></div></div></div><div id="Sec5" class="sec"><h3 id="Sec5title">Ammonium chloride inhibits SARS-CoV infection of Vero E6 cells</h3><p id="idm140144750943488" class="p p-first-last">Since chloroquine inhibited SARS-CoV infection when added before or after infection, we hypothesized that another common lysosomotropic agent, NH<sub>4</sub>Cl, might also function in a similar manner. Ammonium chloride has been widely used in studies addressing endosome-mediated virus entry. Coincidently, NH<sub>4</sub>Cl was recently shown to reduce the transduction of pseudotype viruses decorated with SARS-CoV spike protein [<a href="#CR17" rid="CR17" class=" bibr popnode">17</a>, <a href="#CR18" rid="CR18" class=" bibr popnode">18</a>]. In an attempt to examine if NH<sub>4</sub>Cl functions similarly to chloroquine, we performed infection analyses in Vero E6 cells before (Fig. <a href="/pmc/articles/PMC1232869/figure/Fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig4" rid-ob="ob-Fig4" co-legend-rid="lgnd_Fig4"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">(Fig.4A)</span></span><span>4A</span></a>) and after (Fig. <a href="/pmc/articles/PMC1232869/figure/Fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig4" rid-ob="ob-Fig4" co-legend-rid="lgnd_Fig4"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">(Fig.4B)</span></span><span>4B</span></a>) they were treated with various concentrations of NH<sub>4</sub>Cl. In both cases, we observed a 93&#x02013;99% inhibition with NH<sub>4</sub>Cl at &#x02265; 5 mM. These data indicated that NH<sub>4</sub>Cl (&#x02265; 5 mM) and chloroquine (&#x02265; 10 &#x003bc;M) are very effective in reducing SARS-CoV infection. These results suggest that effects of chloroquine and NH<sub>4</sub>Cl in controlling SARS CoV infection and spread might be mediated by similar mechanism(s).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="Fig4" co-legend-rid="lgnd_Fig4"><a href="/pmc/articles/PMC1232869/figure/Fig4/" target="figure" rid-figpopup="Fig4" rid-ob="ob-Fig4"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140144750115520" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12985_2005_Article_84_Fig4_HTML.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is 12985_2005_Article_84_Fig4_HTML.jpg" src="/pmc/articles/PMC1232869/bin/12985_2005_Article_84_Fig4_HTML.jpg" /></div><div id="largeobj_idm140144750115520" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC1232869/figure/Fig4/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig4"><div><a class="figpopup" href="/pmc/articles/PMC1232869/figure/Fig4/" target="figure" rid-figpopup="Fig4" rid-ob="ob-Fig4">Figure 4</a></div><!--caption a7--><div class="caption"><p id="idm140144750117280"><strong>NH</strong><sub><strong>4</strong></sub><strong>Cl inhibits SARS-CoV during pre or post infection treatment</strong>. NH<sub>4</sub>Cl was added to the cells either before (A) or after (B) infection, similar to what was done for chloroquine in Figs 1 and 2. Antigen-positive cells were counted, and the results were presented as in Fig. 1B.</p></div></div></div></div><div id="Sec6" class="sec"><h3 id="Sec6title">Effect of chloroquine and NH<sub>4</sub>Cl on cell surface expression of ACE2</h3><p id="idm140144747093728" class="p p-first">We performed additional experiments to elucidate the mechanism of SARS-CoV inhibition by chloroquine and NH<sub>4</sub>Cl. Since intra-vesicular acidic pH regulates cellular functions, including N-glycosylation trimming, cellular trafficking, and various enzymatic activities, it was of interest to characterize the effect of both drugs on the processing, glycosylation, and cellular sorting of SARS-CoV spike glycoprotein and its receptor, ACE2. Flow cytometry analysis was performed on Vero E6 cells that were either untreated or treated with highly effective anti-SARS-CoV concentrations of chloroquine or NH<sub>4</sub>Cl. The results revealed that neither drug caused a significant change in the levels of cell-surface ACE2, indicating that the observed inhibitory effects on SARS-CoV infection are not due to the lack of available cell-surface ACE2 (Fig. <a href="/pmc/articles/PMC1232869/figure/Fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig5" rid-ob="ob-Fig5" co-legend-rid="lgnd_Fig5"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">(Fig.5A).</span></span><span>5A</span></a>). We next analyzed the molecular forms of endogenous ACE2 in untreated Vero E6 cells and in cells that were pre-incubated for 1 h with various concentrations of either NH<sub>4</sub>Cl (2.5&#x02013;10 mM) or chloroquine (1 and 10 &#x003bc;M) and labeled with <sup>35</sup>S-(Met) for 3 h in the presence or absence of the drugs (Fig. <a href="/pmc/articles/PMC1232869/figure/Fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig5" rid-ob="ob-Fig5" co-legend-rid="lgnd_Fig5"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">(Fig.5B</span></span><span>5B</span></a> and <a href="/pmc/articles/PMC1232869/figure/Fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig5" rid-ob="ob-Fig5" co-legend-rid="lgnd_Fig5"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -1.5em;">and5C).</span></span><span>5C</span></a>). Under normal conditions, we observed two immunoreactive ACE2 forms, migrating at ~105 and ~113 kDa, respectively (Fig. <a href="/pmc/articles/PMC1232869/figure/Fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig5" rid-ob="ob-Fig5" co-legend-rid="lgnd_Fig5"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">(Fig.5B,</span></span><span>5B</span></a>, lane 1). The ~105-kDa protein is endoglycosidase H sensitive, suggesting that it represents the endoplasmic reticulum (ER) localized form, whereas the ~113-kDa protein is endoglycosidase H resistant and represents the Golgi-modified form of ACE2 [<a href="#CR19" rid="CR19" class=" bibr popnode">19</a>]. The specificity of the antibody was confirmed by displacing the immunoreactive protein bands with excess cold-soluble human recombinant ACE2 (+ rhACE2; Fig. <a href="/pmc/articles/PMC1232869/figure/Fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig5" rid-ob="ob-Fig5" co-legend-rid="lgnd_Fig5"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2em;">Fig.5B,</span></span><span>5B</span></a>, lane 2). When we analyzed ACE2 forms in the presence of NH<sub>4</sub>Cl, a clear stepwise increase in the migration of the ~113-kDa protein was observed with increasing concentrations of NH<sub>4</sub>Cl, with a maximal effect observed at 10 mM NH<sub>4</sub>Cl, resulting in only the ER form of ACE2 being visible on the gel (Fig. <a href="/pmc/articles/PMC1232869/figure/Fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig5" rid-ob="ob-Fig5" co-legend-rid="lgnd_Fig5"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">(Fig.5B,</span></span><span>5B</span></a>, compare lanes 3&#x02013;5). This suggested that the trimming and/or terminal modifications of the N-glycosylated chains of ACE2 were affected by NH<sub>4</sub>Cl treatment. In addition, at 10 mM NH<sub>4</sub>Cl, the ER form of ACE2 migrated with slightly faster mobility, indicating that NH<sub>4</sub>Cl at that concentration might also affect core glycosylation. We also examined the terminal glycosylation status of ACE2 when the cells were treated with chloroquine (Fig. <a href="/pmc/articles/PMC1232869/figure/Fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig5" rid-ob="ob-Fig5" co-legend-rid="lgnd_Fig5"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">(Fig.5C).</span></span><span>5C</span></a>). Similar to NH<sub>4</sub>Cl, a stepwise increase in the electrophoretic mobility of ACE2 was observed with increasing concentrations of chloroquine. At 25 &#x003bc;M chloroquine, the faster electrophoretic mobility of the Golgi-modified form of ACE2 was clearly evident. On the basis of the flow cytometry and immunoprecipitation analyses, it can be inferred that NH<sub>4</sub>Cl and chloroquine both impaired the terminal glycosylation of ACE2, while NH<sub>4</sub>Cl resulted in a more dramatic effect. Although ACE2 is expressed in similar quantities at the cell surface, the variations in its glycosylation status might render the ACE2-SARS-CoV interaction less efficient and inhibit virus entry when the cells are treated with NH<sub>4</sub>Cl and chloroquine.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="Fig5" co-legend-rid="lgnd_Fig5"><a href="/pmc/articles/PMC1232869/figure/Fig5/" target="figure" rid-figpopup="Fig5" rid-ob="ob-Fig5"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140144785743168" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12985_2005_Article_84_Fig5_HTML.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is 12985_2005_Article_84_Fig5_HTML.jpg" src="/pmc/articles/PMC1232869/bin/12985_2005_Article_84_Fig5_HTML.jpg" /></div><div id="largeobj_idm140144785743168" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC1232869/figure/Fig5/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig5"><div><a class="figpopup" href="/pmc/articles/PMC1232869/figure/Fig5/" target="figure" rid-figpopup="Fig5" rid-ob="ob-Fig5">Figure 5</a></div><!--caption a7--><div class="caption"><p id="idm140144741068960"><strong>Effect of lysomotropic agents on the cell-surface expression and biosynthesis of ACE2</strong>. <strong>(A)</strong> Vero E6 cells were cultured for 20 h in the absence (control) or presence of chloroquine (10 &#x003bc;M) or NH<sub>4</sub>Cl (20 mM). Cells were labeled with anti-ACE2 (grey histogram) or with a secondary antibody alone (white histogram). <strong>(B)</strong> Biosynthesis of ACE2 in untreated cells or in cells treated with NH<sub>4</sub>Cl. Vero E6 cells were pulse-labeled for 3 h with <sup>35</sup>S-Met, and the cell lysates were immunoprecipitated with an ACE2 antibody (lane 1). Preincunbation of the antibody with recombinant human ACE2 (rhACE2) completely abolished the signal (lane 2). The positions of the endoglycosidase H-sensitive ER form and the endoglycosidase H-resistant Golgi form of ACE2 are emphasized. Note that the increasing concentration of NH<sub>4</sub>Cl resulting in the decrease of the Golgi form of ACE2. <strong>(C)</strong> A similar experiment was performed in the presence of the indicated concentrations of chloroquine. Note the loss of terminal glycans with increasing concentrations of chloroquine. <strong>(D)</strong> The terminal glycosidic modification of ACE2 was evaluated by neuraminidase treatment of immunoprecipitated ACE2. Here cells were treated with 1&#x02013;25 &#x003bc;M concentrations of chloroquine during starvation, pulse, and 3-h chase.</p></div></div></div><p id="idm140144749353536" class="p p-last">To confirm that ACE2 undergoes terminal sugar modifications and that the terminal glycosylation is affected by NH<sub>4</sub>Cl or chloroquine treatment, we performed immunopreipitation of <sup>35</sup>S-labeled ACE2 and subjected the immunoprecipitates to neuraminidase digestion. Proteins were resolved using SDS-PAGE (Fig <a href="/pmc/articles/PMC1232869/figure/Fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig5" rid-ob="ob-Fig5" co-legend-rid="lgnd_Fig5"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2em;">(Fig5D).</span></span><span>5D</span></a>). It is evident from the slightly faster mobility of the Golgi form of ACE2 after neuraminidase treatment (Fig <a href="/pmc/articles/PMC1232869/figure/Fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig5" rid-ob="ob-Fig5" co-legend-rid="lgnd_Fig5"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2em;">(Fig5D,</span></span><span>5D</span></a>, compare lanes 1 and 2), that ACE2 undergoes terminal glycosylation; however, the ER form of ACE2 was not affected by neuraminidase. Cells treated with 10 &#x003bc;M chloroquine did not result in a significant shift; whereas 25 &#x003bc;M chloroquine caused the Golgi form of ACE2 to resolve similar to the neuraminidase-treated ACE2 (Fig <a href="/pmc/articles/PMC1232869/figure/Fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig5" rid-ob="ob-Fig5" co-legend-rid="lgnd_Fig5"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2em;">(Fig5D,</span></span><span>5D</span></a>, compare lanes 5 and 6). These data provide evidence that ACE2 undergoes terminal glycosylation and that chloroquine at anti-SARS-CoV concentrations abrogates the process.</p></div><div id="Sec7" class="sec sec-last"><h3 id="Sec7title">Effect of chloroquine and NH<sub>4</sub>Cl on the biosynthesis and processing of SARS-CoV spike protein</h3><p id="idm140144742810512" class="p p-first">We next addressed whether the lysosomotropic drugs (NH<sub>4</sub>Cl and chloroquine) affect the biosynthesis, glycosylation, and/or trafficking of the SARS-CoV spike glycoprotein. For this purpose, Vero E6 cells were infected with SARS-CoV for 18 h. Chloroquine or ammonium chloride was added to these cells during while they were being starved (1 h), labeled (30 min) or chased (3 h). The cell lysates were analyzed by immunoprecipitation with the SARS-specific polyclonal antibody (HMAF). The 30-min pulse results indicated that pro-spike (proS) was synthesized as a ~190-kDa precursor (proS-ER) and processed into ~125-, ~105-, and ~80-kDa proteins (Fig. <a href="/pmc/articles/PMC1232869/figure/Fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig6" rid-ob="ob-Fig6" co-legend-rid="lgnd_Fig6"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">(Fig.6A,</span></span><span>6A</span></a>, lane 2), a result identical to that in our previous analysis [<a href="#CR6" rid="CR6" class=" bibr popnode">6</a>]. Except for the 100 &#x003bc;M chloroquine (Fig. <a href="/pmc/articles/PMC1232869/figure/Fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig6" rid-ob="ob-Fig6" co-legend-rid="lgnd_Fig6"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">(Fig.6A,</span></span><span>6A</span></a>, lane 3), there was no significant difference in the biosynthesis or processing of the virus spike protein in untreated or chloroquine-treated cells (Fig. <a href="/pmc/articles/PMC1232869/figure/Fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig6" rid-ob="ob-Fig6" co-legend-rid="lgnd_Fig6"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">(Fig.6A,</span></span><span>6A</span></a>, lanes 4&#x02013;6). It should be noted that chloroquine at 100 &#x003bc;M resulted in an overall decrease in biosynthesis and in the levels of processed virus glycoprotein. In view of the lack of reduction in the biosynthesis and processing of the spike glycoprotein in the presence of chloroquine concentrations (10 and 50 &#x003bc;M) that caused large reductions in SARS-CoV replication and spread, we conclude that the antiviral effect is probably not due to alteration of virus glycoprotein biosynthesis and processing. Similar analyses were performed with NH<sub>4</sub>Cl, and the data suggested that the biosynthesis and processing of the spike protein were also not negatively affected by NH<sub>4</sub>Cl (Fig. <a href="/pmc/articles/PMC1232869/figure/Fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig6" rid-ob="ob-Fig6" co-legend-rid="lgnd_Fig6"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">(Fig.6A,</span></span><span>6A</span></a>, lanes 7&#x02013;12). Consistent with our previous analysis [<a href="#CR6" rid="CR6" class=" bibr popnode">6</a>], we observed the presence of a larger protein, which is referred to here as oligomers. Recently, Song et al. [<a href="#CR20" rid="CR20" class=" bibr popnode">20</a>] provided evidence that these are homotrimers of the SARS-CoV spike protein and were incorporated into the virions. Interestingly, the levels of the homotrimers in cells treated with 100 &#x003bc;M chloroquine and 40 and 20 mM NH<sub>4</sub>Cl (Fig. <a href="/pmc/articles/PMC1232869/figure/Fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig6" rid-ob="ob-Fig6" co-legend-rid="lgnd_Fig6"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">(Fig.6A,</span></span><span>6A</span></a>, lanes 3, 9, and 10) were slightly lower than in control cells or cells treated with lower drug concentrations.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="Fig6" co-legend-rid="lgnd_Fig6"><a href="/pmc/articles/PMC1232869/figure/Fig6/" target="figure" rid-figpopup="Fig6" rid-ob="ob-Fig6"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140144741823984" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12985_2005_Article_84_Fig6_HTML.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is 12985_2005_Article_84_Fig6_HTML.jpg" src="/pmc/articles/PMC1232869/bin/12985_2005_Article_84_Fig6_HTML.jpg" /></div><div id="largeobj_idm140144741823984" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC1232869/figure/Fig6/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig6"><div><a class="figpopup" href="/pmc/articles/PMC1232869/figure/Fig6/" target="figure" rid-figpopup="Fig6" rid-ob="ob-Fig6">Figure 6</a></div><!--caption a7--><div class="caption"><p id="idm140144785217920"><strong>Effects of NH</strong><sub><strong>4</strong></sub><strong>Cl and chloroquine (CQ) on the biosynthesis, processing, and glycosylation of SARS-CoV spike protein</strong>. Vero E6 cells were infected with SARS-CoV as described in Fig. 2. CQ or NH<sub>4</sub>Cl was added during the periods of starvation (1 h) and labeling (30 min) with <sup>35</sup>S-Cys and followed by chase for 3 h in the presence of unlabeled medium. Cells were lysed in RIPA buffer and immunoprecipitated with HMAF. Virus proteins were resolved using 3&#x02013;8% NuPAGE gel (Invitrogen). The cells presented were labeled for 30 min <strong>(A)</strong> and chased for 3 h <strong>(B)</strong>. The migration positions of the various spike molecular forms are indicated at the right side, and those of the molecular standards are shown to the left side. proS-ER and proS-Golgi are the pro-spike of SARS-Co in the ER and Golgi compartments, respectively and proS-ungly is the unglycosylated pro-spike ER.</p></div></div></div><p id="idm140144741822896" class="p p-last">The data obtained from a 30-min pulse followed by a 3-h chase (Fig. <a href="/pmc/articles/PMC1232869/figure/Fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig6" rid-ob="ob-Fig6" co-legend-rid="lgnd_Fig6"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">(Fig.6B,</span></span><span>6B</span></a>, lanes 2 and 8) confirmed our earlier observation that the SARS-CoV spike protein precursor (proS-ER) acquires Golgi-specific modifications (proS-Golgi) resulting in a ~210-kDa protein [<a href="#CR6" rid="CR6" class=" bibr popnode">6</a>]. Chloroquine at 10, 25, and 50 &#x003bc;M had no substantial negative impact on the appearance of the Golgi form (Fig. <a href="/pmc/articles/PMC1232869/figure/Fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig6" rid-ob="ob-Fig6" co-legend-rid="lgnd_Fig6"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">(Fig.6B,</span></span><span>6B</span></a>, compare lane 2 to lanes 4&#x02013;6). Only at 100 &#x003bc;M chloroquine was a reduction in the level of the Golgi-modified pro-spike observed (lane 3). On the other hand, NH<sub>4</sub>Cl abrogated the appearance of Golgi-modified forms at &#x02265;10 mM (compare lane 8 with 9&#x02013;11) and had a milder effect at 1 mM (lane 12). These data clearly demonstrate that the biosynthesis and proteolytic processing of SARS-CoV spike protein are not affected at chloroquine (25 and 50 &#x003bc;M) and NH<sub>4</sub>Cl (1 mM) doses that cause virus inhibitory effects. In addition, with 40, 20, and 10 mM NH<sub>4</sub>Cl, there was an increased accumulation of proS-ER with a concomitant decrease in the amount of oligomers (Fig. <a href="/pmc/articles/PMC1232869/figure/Fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig6" rid-ob="ob-Fig6" co-legend-rid="lgnd_Fig6"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">(Fig.6B,</span></span><span>6B</span></a>, lanes 9&#x02013;11). When we examined the homotrimers, we found that chloroquine at 100 &#x003bc;M and NH<sub>4</sub>Cl at 40 and 20 mM resulted in slightly faster mobility of the trimers (Fig. <a href="/pmc/articles/PMC1232869/figure/Fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig6" rid-ob="ob-Fig6" co-legend-rid="lgnd_Fig6"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">(Fig.6B,</span></span><span>6B</span></a>, lanes 3, 9, and 10), but lower drug doses, which did exhibit significant antiviral effects, did not result in appreciable differences. These data suggest that the newly synthesized intracellular spike protein may not be a major target for chloroquine and NH<sub>4</sub>Cl antiviral action. The faster mobility of the trimer at certain higher concentration of the drugs might be due the effect of these drugs on the terminal glycosylation of the trimers.</p></div></div><div id="Sec8" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec8title">Discussion</h2><p id="idm140144785971984" class="p p-first">We have identified chloroquine as an effective antiviral agent for SARS-CoV in cell culture conditions, as evidenced by its inhibitory effect when the drug was added prior to infection or after the initiation and establishment of infection. The fact that chloroquine exerts an antiviral effect during pre- and post-infection conditions suggest that it is likely to have both prophylactic and therapeutic advantages. Recently, Keyaerts et al. [<a href="#CR21" rid="CR21" class=" bibr popnode">21</a>] reported the antiviral properties of chloroquine and identified that the drug affects SARS-CoV replication in cell culture, as evidenced by quantitative RT-PCR. Taken together with the findings of Keyaerts et al. [<a href="#CR21" rid="CR21" class=" bibr popnode">21</a>], our analysis provides further evidence that chloroquine is effective against SARS-CoV Frankfurt and Urbani strains. We have provided evidence that chloroquine is effective in preventing SARS-CoV infection in cell culture if the drug is added to the cells 24 h prior to infection. In addition, chloroquine was significantly effective even when the drug was added 3&#x02013;5 h after infection, suggesting an antiviral effect even after the establishment of infection. Since similar results were obtained by NH<sub>4</sub>Cl treatment of Vero E6 cells, the underlying mechanism(s) of action of these drugs might be similar.</p><p id="idm140144744228832">Apart from the probable role of chloroquine on SARS-CoV replication, the mechanisms of action of chloroquine on SARS-CoV are not fully understood. Previous studies have suggested the elevation of pH as a mechanism by which chloroquine reduces the transduction of SARS-CoV pseudotype viruses [<a href="#CR17" rid="CR17" class=" bibr popnode">17</a>, <a href="#CR18" rid="CR18" class=" bibr popnode">18</a>]. We examined the effect of chloroquine and NH<sub>4</sub>Cl on the SARS-CoV spike proteins and on its receptor, ACE2. Immunoprecipitation results of ACE2 clearly demonstrated that effective anti-SARS-CoV concentrations of chloroquine and NH<sub>4</sub>Cl also impaired the terminal glycosylation of ACE2. However, the flow cytometry data demonstrated that there are no significant differences in the cell surface expression of ACE2 in cells treated with chloroquine or NH<sub>4</sub>Cl. On the basis of these results, it is reasonable to suggest that the pre-treatment with NH<sub>4</sub>Cl or chloroquine has possibly resulted in the surface expression of the under-glycosylated ACE2. In the case of chloroquine treatment prior to infection, the impairment of terminal glycosylation of ACE2 may result in reduced binding affinities between ACE2 and SARS-CoV spike protein and negatively influence the initiation of SARS-CoV infection. Since the biosynthesis, processing, Golgi modification, and oligomerization of the newly synthesized spike protein were not appreciably affected by anti-SARS-CoV concentrations of either chloroquine or NH<sub>4</sub>Cl, we conclude that these events occur in the cell independent of the presence of the drugs. The potential contribution of these drugs in the elevation of endosomal pH and its impact on subsequent virus entry or exit could not be ruled out. A decrease in SARS-CoV pseudotype transduction in the presence of NH<sub>4</sub>Cl was observed and was attributed to the effect on intracellular pH [<a href="#CR17" rid="CR17" class=" bibr popnode">17</a>, <a href="#CR18" rid="CR18" class=" bibr popnode">18</a>]. When chloroquine or NH<sub>4</sub>Cl are added after infection, these agents can rapidly raise the pH and subvert on-going fusion events between virus and endosomes, thus inhibiting the infection.</p><p id="idm140144746582960">In addition, the mechanism of action of NH<sub>4</sub>Cl and chloroquine might depend on when they were added to the cells. When added after the initiation of infection, these drugs might affect the endosome-mediated fusion, subsequent virus replication, or assembly and release. Previous studies of chloroquine have demonstrated that it has multiple effects on mammalian cells in addition to the elevation of endosomal pH, including the prevention of terminal glycosyaltion of immunoglobulins [<a href="#CR22" rid="CR22" class=" bibr popnode">22</a>]. When added to virus-infected cells, chloroquine inhibited later stages in vesicular stomatitis virus maturation by inhibiting the glycoprotein expression at the cell surface [<a href="#CR23" rid="CR23" class=" bibr popnode">23</a>], and it inhibited the production of infectious HIV-1 particles by interfering with terminal glycosylation of the glycoprotein [<a href="#CR24" rid="CR24" class=" bibr popnode">24</a>, <a href="#CR25" rid="CR25" class=" bibr popnode">25</a>]. On the basis of these properties, we suggest that the cell surface expression of under-glycosylated ACE2 and its poor affinity to SARS-CoV spike protein may be the primary mechanism by which infection is prevented by drug pretreatment of cells prior to infection. On the other hand, rapid elevation of endosomal pH and abrogation of virus-endosome fusion may be the primary mechanism by which virus infection is prevented under post-treatment conditions. More detailed SARS CoV spike-ACE2 binding assays in the presence or absence of chloroquine will be performed to confirm our findings. Our studies indicate that the impact of NH<sub>4</sub>Cl and chloroquine on the ACE2 and spike protein profiles are significantly different. NH<sub>4</sub>Cl exhibits a more pronounced effect than does chloroquine on terminal glycosylation, highlighting the novel intricate differences between chloroquine and ammonium chloride in affecting the protein transport or glycosylation of SARS-CoV spike protein and its receptor, ACE2, despite their well-established similar effects of endosomal pH elevation.</p><p id="idm140144741502256" class="p p-last">The infectivity of coronaviruses other than SARS-CoV are also affected by chloroquine, as exemplified by the human CoV-229E [<a href="#CR15" rid="CR15" class=" bibr popnode">15</a>]. The inhibitory effects observed on SARS-CoV infectivity and cell spread occurred in the presence of 1&#x02013;10 &#x003bc;M chloroquine, which are plasma concentrations achievable during the prophylaxis and treatment of malaria (varying from 1.6&#x02013;12.5 &#x003bc;M) [<a href="#CR26" rid="CR26" class=" bibr popnode">26</a>] and hence are well tolerated by patients. It recently was speculated that chloroquine might be effective against SARS and the authors suggested that this compound might block the production of TNF&#x003b1;, IL6, or IFN&#x003b3; [<a href="#CR15" rid="CR15" class=" bibr popnode">15</a>]. Our data provide evidence for the possibility of using the well-established drug chloroquine in the clinical management of SARS.</p></div><div id="Sec9" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec9title">Conclusion</h2><p id="idm140144750664736" class="p p-first-last">Chloroquine, a relatively safe, effective and cheap drug used for treating many human diseases including malaria, amoebiosis and human immunodeficiency virus is effective in inhibiting the infection and spread of SARS CoV in cell culture. The fact that the drug has significant inhibitory antiviral effect when the susceptible cells were treated either prior to or after infection suggests a possible prophylactic and therapeutic use.</p></div><div id="Sec10" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec10title">Methods</h2><div id="Sec11" class="sec sec-first"><h3 id="Sec11title">SARS-CoV infection, immunofluorescence, and immunoprecipitation analyses</h3><p id="idm140144750662784" class="p p-first">Vero E6 cells (an African green monkey kidney cell line) were infected with SARS-CoV (Urbani strain) at a multiplicity of infection of 0.5 for 1 h. The cells were washed with PBS and then incubated in OPTI-MEM (Invitrogen) medium with or without various concentrations of either chloroquine or NH<sub>4</sub>Cl (both from Sigma). Immunofluorescence staining was performed with SARS-CoV-specific hyperimmune mouse ascitic fluid (HMAF) [<a href="#CR8" rid="CR8" class=" bibr popnode">8</a>] followed by anti-mouse fluorescein-coupled antibody.</p><p id="idm140144744791920" class="p p-last">Eighteen hours after infection, the virus-containing supernatants were removed, and the cells were pulsed with <sup>35</sup>S-(Cys) for 30 min and chased for 3 h before lysis in RIPA buffer. Clarified cell lysates and media were incubated with HMAF, and immunoprecipitated proteins were separated by 3&#x02013;8% NuPAGE gel (Invitrogen); proteins were visualized by autoradiography. In some experiments, cells were chased for 3 h with isotope-free medium. Clarified cell supernatants were also immunoprecipitated with SARS-CoV-specific HMAF.</p></div><div id="Sec12" class="sec sec-last"><h3 id="Sec12title">ACE2 flow cytometry analysis and biosynthesis</h3><p id="idm140144744790096" class="p p-first-last">Vero E6 cells were seeded in Dulbecco\'s modified Eagle medium (Invitrogen) supplemented with 10% fetal bovine serum. The next day, the cells were incubated in Opti-MEM (Invitrogen) in the presence or absence of 10 &#x003bc;M chloroquine or 20 mM NH<sub>4</sub>Cl. To analyze the levels of ACE2 at the cell surface, cells were incubated on ice with 10 &#x003bc;g/mL affinity-purified goat anti-ACE2 antibody (R&#x00026;D Systems) and then incubated with FITC-labeled swine anti-goat IgG antibody (Caltag Laboratories). Labeled cells were analyzed by flow cytometry with a FACSCalibur flow cytometer (BD Biosciences). For ACE2 biosynthesis studies, Vero E6 cells were pulsed with 250 &#x003bc;Ci <sup>35</sup>S-(Met) (Perkin Elmer) for 3 h with the indicated concentrations of chloroquine or NH<sub>4</sub>Cl and then lysed in RIPA buffer. Clarified lysates were immunoprecipitated with an affinity-purified goat anti-ACE2 antibody (R&#x00026;D systems), and the immunoprecipitated proteins were separated by SDS-polyacrylamide gel electrophoresis.</p></div></div><div id="idm140144821878592" class="tsec sec"><h2 class="head no_bottom_margin" id="idm140144821878592title">Acknowledgements</h2><div class="sec"><p id="idm140144821878208">We thank Claudia Chesley and Jonathan Towner for critical reading of the manuscript. This work was supported by a Canadian PENCE grant (T3), CIHR group grant #MGC 64518, and CIHR grant #MGP-44363 (to NGS).</p></div></div><div id="App1" class="tsec sec headless whole_rhythm"><!--/article/back/app-group/app/--><div id="Sec13" class="sec sec-first"><h3 id="Sec13title">Authors&#x02019; original submitted files for images</h3><p id="idm140144747699888" class="p p-first-last">Below are the links to the authors&#x02019; original submitted files for images.<span class="sup-box" id="MOESM1"><a href="/pmc/articles/PMC1232869/bin/12985_2005_84_MOESM1_ESM.tiff" data-ga-action="click_feat_suppl">Authors&#x02019; original file for figure 1</a><sup>(239K, tiff)</sup></span><span class="sup-box" id="MOESM2"><a href="/pmc/articles/PMC1232869/bin/12985_2005_84_MOESM2_ESM.tiff" data-ga-action="click_feat_suppl">Authors&#x02019; original file for figure 2</a><sup>(388K, tiff)</sup></span><span class="sup-box" id="MOESM3"><a href="/pmc/articles/PMC1232869/bin/12985_2005_84_MOESM3_ESM.tiff" data-ga-action="click_feat_suppl">Authors&#x02019; original file for figure 3</a><sup>(503K, tiff)</sup></span><span class="sup-box" id="MOESM4"><a href="/pmc/articles/PMC1232869/bin/12985_2005_84_MOESM4_ESM.tiff" data-ga-action="click_feat_suppl">Authors&#x02019; original file for figure 4</a><sup>(62K, tiff)</sup></span><span class="sup-box" id="MOESM5"><a href="/pmc/articles/PMC1232869/bin/12985_2005_84_MOESM5_ESM.tiff" data-ga-action="click_feat_suppl">Authors&#x02019; original file for figure 5</a><sup>(239K, tiff)</sup></span><span class="sup-box" id="MOESM6"><a href="/pmc/articles/PMC1232869/bin/12985_2005_84_MOESM6_ESM.tiff" data-ga-action="click_feat_suppl">Authors&#x02019; original file for figure 6</a><sup>(229K, tiff)</sup></span></p></div></div><div id="idm140144751360912" class="tsec sec"><h2 class="head no_bottom_margin" id="idm140144751360912title">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="idm140144751360784"><p id="idm140144751360656" class="p p-first"><strong>Competing interests</strong></p><p id="idm140144751360272" class="p p-last">The author(s) declare that they have no competing interests.</p></p><p class="fn sec" id="idm140144751360016"><p id="idm140144751359888" class="p p-first"><strong>Authors\' contributions</strong></p><p id="idm140144751359504" class="p p-last">MV did all the experiments pertaining to SARS CoV infection and coordinated the drafting of the manuscript. EB and SB performed experiments on ACE2 biosynthesis and FACS analysis. BE performed data acquisition from the immunofluorescence experiments. PR and TK provided critical reagents and revised the manuscript critically. NS and SN along with MV and EB participated in the planning of the experiments, review and interpretation of data and critical review of the manuscript. All authors read and approved the content of the manuscript.</p></p></div></div><div id="idm140144741697712aff-info" class="tsec sec"><h2 class="head no_bottom_margin" id="idm140144741697712aff-infotitle">Contributor Information</h2><p><span class="fm-affl">Martin J Vincent, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.cdc@tnecnivm" class="oemail">vog.cdc@tnecnivm</a></span>.</p><p><span class="fm-affl">Eric Bergeron, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ac.cq.mcri@eregreb" class="oemail">ac.cq.mcri@eregreb</a></span>.</p><p><span class="fm-affl">Suzanne Benjannet, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ac.cq.mcri@snajneb" class="oemail">ac.cq.mcri@snajneb</a></span>.</p><p><span class="fm-affl">Bobbie R Erickson, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.cdc@1noskcirEB" class="oemail">vog.cdc@1noskcirEB</a></span>.</p><p><span class="fm-affl">Pierre E Rollin, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.cdc@nilloRP" class="oemail">vog.cdc@nilloRP</a></span>.</p><p><span class="fm-affl">Thomas G Ksiazek, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.cdc@kezaisKT" class="oemail">vog.cdc@kezaisKT</a></span>.</p><p><span class="fm-affl">Nabil G Seidah, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ac.cq.mcri@nhadies" class="oemail">ac.cq.mcri@nhadies</a></span>.</p><p><span class="fm-affl">Stuart T Nichol, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.cdc@lohciNS" class="oemail">vog.cdc@lohciNS</a></span>.</p></div><div id="Bib1" class="tsec sec"><h2 class="head no_bottom_margin" id="Bib1title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="CR1">1. <span class="element-citation">Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, Tong S, Urbani C, Comer JA, Lim W, Rollin PE, Dowell SF, Ling AE, Humphrey CD, Shieh WJ, Guarner J, Paddock CD, Rota PB, Fields B, DeRisi J, Yang JY, Cox N, Hughes J, LeDuc JW, Bellini WJ, Anderson LJ, SARS Working Group  A novel coronavirus associated with severe acute respiratory syndrome. <span><span class="ref-journal">N Engl J Med. </span>2003;<span class="ref-vol">348</span>:1953\xe2\x80\x931966. doi: 10.1056/NEJMoa030781.</span> [<a href="/pubmed/12690092" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1056%2FNEJMoa030781" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=A+novel+coronavirus+associated+with+severe+acute+respiratory+syndrome&amp;author=TG+Ksiazek&amp;author=D+Erdman&amp;author=CS+Goldsmith&amp;author=SR+Zaki&amp;author=T+Peret&amp;volume=348&amp;publication_year=2003&amp;pages=1953-1966&amp;pmid=12690092&amp;doi=10.1056/NEJMoa030781&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR2">2. <span class="element-citation">Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YS, Khattra J, Asano JK, Barber SA, Chan SY, Cloutier A, Coughlin SM, Freeman D, Girn N, Griffith OL, Leach SR, Mayo, McDonald H, Montgomery SB, Pandoh PK, Petrescu AS, Robertson AG, Schein JE, Siddiqui A, Smailus DE, Stott JM, Yang GS, Plummer F, Andonov A, Artsob H, Bastien N, Bernard K, Booth TF, Bowness D, Czub M, Drebot M, Fernando L, Flick R, Garbutt M, Gray M, Grolla A, Jones S, Feldmann H, Meyers A, Kabani A, Li Y, Normand S, Stroher U, Tipples GA, Tyler S, Vogrig R, Ward D, Watson B, Brunham RC, Krajden M, Petric M, Skowronski DM, Upton C, Roper RL. The Genome sequence of the SARS-associated coronavirus. <span><span class="ref-journal">Science. </span>2003;<span class="ref-vol">300</span>:1399\xe2\x80\x931404. doi: 10.1126/science.1085953.</span> [<a href="/pubmed/12730501" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1126%2Fscience.1085953" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=The+Genome+sequence+of+the+SARS-associated+coronavirus&amp;author=MA+Marra&amp;author=SJ+Jones&amp;author=CR+Astell&amp;author=RA+Holt&amp;author=A+Brooks-Wilson&amp;volume=300&amp;publication_year=2003&amp;pages=1399-1404&amp;pmid=12730501&amp;doi=10.1126/science.1085953&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR3">3. <span class="element-citation">Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Penaranda S, Bankamp B, Maher K, Chen MH, Tong S, Tamin A, Lowe L, Frace M, DeRisi JL, Chen Q, Wang D, Erdman DD, Peret TC, Burns C, Ksiazek TG, Rollin PE, Sanchez A, Liffick S, Holloway B, Limor J, McCaustland K, Olsen Rasmussen M, Fouchier R, Gunther S, Osterhaus AS, Drosten C, Pallansch MA, Anderson LJ, Bellini WJ. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. <span><span class="ref-journal">Science. </span>2003;<span class="ref-vol">300</span>:1394\xe2\x80\x931399. doi: 10.1126/science.1085952.</span> [<a href="/pubmed/12730500" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1126%2Fscience.1085952" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Characterization+of+a+novel+coronavirus+associated+with+severe+acute+respiratory+syndrome&amp;author=PA+Rota&amp;author=MS+Oberste&amp;author=SS+Monroe&amp;author=WA+Nix&amp;author=R+Campagnoli&amp;volume=300&amp;publication_year=2003&amp;pages=1394-1399&amp;pmid=12730500&amp;doi=10.1126/science.1085952&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR4">4. <span class="element-citation">Ng ML, Tan SH, See EE, Ooi EE, Ling AE. Proliferative growth of SARS coronavirus in Vero E6 cells. <span><span class="ref-journal">J Gen Virol. </span>2003;<span class="ref-vol">84</span>:3291\xe2\x80\x933303. doi: 10.1099/vir.0.19505-0.</span> [<a href="/pubmed/14645910" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1099%2Fvir.0.19505-0" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Gen+Virol&amp;title=Proliferative+growth+of+SARS+coronavirus+in+Vero+E6+cells&amp;author=ML+Ng&amp;author=SH+Tan&amp;author=EE+See&amp;author=EE+Ooi&amp;author=AE+Ling&amp;volume=84&amp;publication_year=2003&amp;pages=3291-3303&amp;pmid=14645910&amp;doi=10.1099/vir.0.19505-0&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR5">5. <span class="element-citation">Li M, Moore WJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. <span><span class="ref-journal">Nature. </span>2003;<span class="ref-vol">426</span>:450\xe2\x80\x93454. doi: 10.1038/nature02145.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7095016/">PMC free article</a>]</span> [<a href="/pubmed/14647384" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1038%2Fnature02145" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Angiotensin-converting+enzyme+2+is+a+functional+receptor+for+the+SARS+coronavirus&amp;author=M+Li&amp;author=WJ+Moore&amp;author=N+Vasilieva&amp;author=J+Sui&amp;author=SK+Wong&amp;volume=426&amp;publication_year=2003&amp;pages=450-454&amp;pmid=14647384&amp;doi=10.1038/nature02145&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR6">6. <span class="element-citation">Bergeron E, Vincent MJ, Wickham L, Hamelin J, Basak A, Nichol ST, Chr&#x000e9;tien M, NG Seidah. Implication of proprotein convertases in the processing and spread of severe acute respiratory syndrome coronavirus. <span><span class="ref-journal">Biochem Biophys Res Comm. </span>2005;<span class="ref-vol">326</span>:554\xe2\x80\x93563. doi: 10.1016/j.bbrc.2004.11.063.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7092861/">PMC free article</a>]</span> [<a href="/pubmed/15596135" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.bbrc.2004.11.063" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochem+Biophys+Res+Comm&amp;title=Implication+of+proprotein+convertases+in+the+processing+and+spread+of+severe+acute+respiratory+syndrome+coronavirus&amp;author=E+Bergeron&amp;author=MJ+Vincent&amp;author=L+Wickham&amp;author=J+Hamelin&amp;author=A+Basak&amp;volume=326&amp;publication_year=2005&amp;pages=554-563&amp;pmid=15596135&amp;doi=10.1016/j.bbrc.2004.11.063&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR7">7. <span class="element-citation">Zhang Y, Li T, Fu L, Yu C, Li Y, Xu X, Wang Y, Ning H, Zhang S, Chen W, Babiuk LA, Chang Z. Silencing SARS-CoV spike protein expression in cultured cells by RNA interference. <span><span class="ref-journal">FEBS Lett. </span>2004;<span class="ref-vol">560</span>:141\xe2\x80\x93146. doi: 10.1016/S0014-5793(04)00087-0.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7127813/">PMC free article</a>]</span> [<a href="/pubmed/14988013" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS0014-5793(04)00087-0" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=FEBS+Lett&amp;title=Silencing+SARS-CoV+spike+protein+expression+in+cultured+cells+by+RNA+interference&amp;author=Y+Zhang&amp;author=T+Li&amp;author=L+Fu&amp;author=C+Yu&amp;author=Y+Li&amp;volume=560&amp;publication_year=2004&amp;pages=141-146&amp;pmid=14988013&amp;doi=10.1016/S0014-5793(04)00087-0&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR8">8. <span class="element-citation">Subbarao K, McAuliffe J, Vogel L, Fahle G, Fischer S, Tatti K, Packard M, Shieh WJ, Zaki S, Murphy B. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. <span><span class="ref-journal">J Virol. </span>2004;<span class="ref-vol">78</span>:3572\xe2\x80\x933577. doi: 10.1128/JVI.78.7.3572-3577.2004.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC371090/">PMC free article</a>]</span> [<a href="/pubmed/15016880" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1128%2FJVI.78.7.3572-3577.2004" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=Prior+infection+and+passive+transfer+of+neutralizing+antibody+prevent+replication+of+severe+acute+respiratory+syndrome+coronavirus+in+the+respiratory+tract+of+mice&amp;author=K+Subbarao&amp;author=J+McAuliffe&amp;author=L+Vogel&amp;author=G+Fahle&amp;author=S+Fischer&amp;volume=78&amp;publication_year=2004&amp;pages=3572-3577&amp;pmid=15016880&amp;doi=10.1128/JVI.78.7.3572-3577.2004&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR9">9. <span class="element-citation">Yang ZY, Kong WP, Huang Y, Roberts A, Murphy BR, Subbarao K, Nabel GJ. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. <span><span class="ref-journal">Nature. </span>2004;<span class="ref-vol">428</span>:561\xe2\x80\x93564. doi: 10.1038/nature02463.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7095382/">PMC free article</a>]</span> [<a href="/pubmed/15024391" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1038%2Fnature02463" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=A+DNA+vaccine+induces+SARS+coronavirus+neutralization+and+protective+immunity+in+mice&amp;author=ZY+Yang&amp;author=WP+Kong&amp;author=Y+Huang&amp;author=A+Roberts&amp;author=BR+Murphy&amp;volume=428&amp;publication_year=2004&amp;pages=561-564&amp;pmid=15024391&amp;doi=10.1038/nature02463&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR10">10. <span class="element-citation">Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, Subbarao K, Moss B. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>2004;<span class="ref-vol">101</span>:6641\xe2\x80\x936646. doi: 10.1073/pnas.0401939101.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC404098/">PMC free article</a>]</span> [<a href="/pubmed/15096611" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1073%2Fpnas.0401939101" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+USA&amp;title=Severe+acute+respiratory+syndrome+coronavirus+spike+protein+expressed+by+attenuated+vaccinia+virus+protectively+immunizes+mice&amp;author=H+Bisht&amp;author=A+Roberts&amp;author=L+Vogel&amp;author=A+Bukreyev&amp;author=PL+Collins&amp;volume=101&amp;publication_year=2004&amp;pages=6641-6646&amp;pmid=15096611&amp;doi=10.1073/pnas.0401939101&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR11">11. <span class="element-citation">Bukreyev A, Lamirande EW, Buchholz UJ, Vogel LN, Elkins WR, St. Claire M, Murphy BR, Subbarao K, Collins PL. Mucosal immunization of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. <span><span class="ref-journal">Lancet. </span>2004;<span class="ref-vol">363</span>:2122\xe2\x80\x932127. doi: 10.1016/S0140-6736(04)16501-X.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7112367/">PMC free article</a>]</span> [<a href="/pubmed/15220033" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS0140-6736(04)16501-X" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Mucosal+immunization+of+African+green+monkeys+(Cercopithecus+aethiops)+with+an+attenuated+parainfluenza+virus+expressing+the+SARS+coronavirus+spike+protein+for+the+prevention+of+SARS&amp;author=A+Bukreyev&amp;author=EW+Lamirande&amp;author=UJ+Buchholz&amp;author=LN+Vogel&amp;author=WR+Elkins&amp;volume=363&amp;publication_year=2004&amp;pages=2122-2127&amp;pmid=15220033&amp;doi=10.1016/S0140-6736(04)16501-X&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR12">12. <span class="element-citation">Sainz B, Jr, Mossel EC, Peters CJ, Garry RF. Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) <span><span class="ref-journal">Virology. </span>2004;<span class="ref-vol">329</span>:11\xe2\x80\x9317. doi: 10.1016/j.virol.2004.08.011.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7111895/">PMC free article</a>]</span> [<a href="/pubmed/15476870" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.virol.2004.08.011" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Virology&amp;title=Interferon-beta+and+interferon-gamma+synergistically+inhibit+the+replication+of+severe+acute+respiratory+syndrome-associated+coronavirus+(SARS-CoV)&amp;author=B+Sainz&amp;author=EC+Mossel&amp;author=CJ+Peters&amp;author=RF+Garry&amp;volume=329&amp;publication_year=2004&amp;pages=11-17&amp;pmid=15476870&amp;doi=10.1016/j.virol.2004.08.011&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR13">13. <span class="element-citation">Stroher U, DiCaro A, Li Y, Strong JE, Aoki F, Plummer F, Jones SM, Feldmann H. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha. <span><span class="ref-journal">J Infect Dis. </span>2004;<span class="ref-vol">189</span>:1164\xe2\x80\x931167. doi: 10.1086/382597.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7109643/">PMC free article</a>]</span> [<a href="/pubmed/15031783" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1086%2F382597" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Infect+Dis&amp;title=Severe+acute+respiratory+syndrome-related+coronavirus+is+inhibited+by+interferon-+alpha&amp;author=U+Stroher&amp;author=A+DiCaro&amp;author=Y+Li&amp;author=JE+Strong&amp;author=F+Aoki&amp;volume=189&amp;publication_year=2004&amp;pages=1164-1167&amp;pmid=15031783&amp;doi=10.1086/382597&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR14">14. <span class="element-citation">Sui J, Li W, Murakami A, Tamin A, Matthews LJ, Wong SK, Moore MJ, Tallarico AS, Olurinde M, Choe H, Anderson LJ, Bellini WJ, Farzan M, Marasco WA. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>2004;<span class="ref-vol">101</span>:2536\xe2\x80\x932541. doi: 10.1073/pnas.0307140101.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC356985/">PMC free article</a>]</span> [<a href="/pubmed/14983044" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1073%2Fpnas.0307140101" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+USA&amp;title=Potent+neutralization+of+severe+acute+respiratory+syndrome+(SARS)+coronavirus+by+a+human+mAb+to+S1+protein+that+blocks+receptor+association&amp;author=J+Sui&amp;author=W+Li&amp;author=A+Murakami&amp;author=A+Tamin&amp;author=LJ+Matthews&amp;volume=101&amp;publication_year=2004&amp;pages=2536-2541&amp;pmid=14983044&amp;doi=10.1073/pnas.0307140101&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR15">15. <span class="element-citation">Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today\'s diseases? <span><span class="ref-journal">Lancet Infect Dis. </span>2003;<span class="ref-vol">3</span>:722\xe2\x80\x93727. doi: 10.1016/S1473-3099(03)00806-5.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7128816/">PMC free article</a>]</span> [<a href="/pubmed/14592603" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS1473-3099(03)00806-5" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet+Infect+Dis&amp;title=Effects+of+chloroquine+on+viral+infections:+an+old+drug+against+today\'s+diseases?&amp;author=A+Savarino&amp;author=JR+Boelaert&amp;author=A+Cassone&amp;author=G+Majori&amp;author=R+Cauda&amp;volume=3&amp;publication_year=2003&amp;pages=722-727&amp;pmid=14592603&amp;doi=10.1016/S1473-3099(03)00806-5&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR16">16. <span class="element-citation">Ng ML, Tan SH, See EE, Ooi EE, Ling AE. Early events of SARS coronavirus infection in vero cells. <span><span class="ref-journal">J Med Virol. </span>2003;<span class="ref-vol">71</span>:323\xe2\x80\x93331. doi: 10.1002/jmv.10499.</span> [<a href="/pubmed/12966536" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1002%2Fjmv.10499" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Med+Virol&amp;title=Early+events+of+SARS+coronavirus+infection+in+vero+cells&amp;author=ML+Ng&amp;author=SH+Tan&amp;author=EE+See&amp;author=EE+Ooi&amp;author=AE+Ling&amp;volume=71&amp;publication_year=2003&amp;pages=323-331&amp;pmid=12966536&amp;doi=10.1002/jmv.10499&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR17">17. <span class="element-citation">Simmons G, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, Bates P. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>2004;<span class="ref-vol">101</span>:4240\xe2\x80\x934245. doi: 10.1073/pnas.0306446101.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC384725/">PMC free article</a>]</span> [<a href="/pubmed/15010527" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1073%2Fpnas.0306446101" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+USA&amp;title=Characterization+of+severe+acute+respiratory+syndrome-associated+coronavirus+(SARS-CoV)+spike+glycoprotein-mediated+viral+entry&amp;author=G+Simmons&amp;author=JD+Reeves&amp;author=AJ+Rennekamp&amp;author=SM+Amberg&amp;author=AJ+Piefer&amp;volume=101&amp;publication_year=2004&amp;pages=4240-4245&amp;pmid=15010527&amp;doi=10.1073/pnas.0306446101&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR18">18. <span class="element-citation">Yang ZY, Huang Y, Ganesh L, Leung K, Kong WP, Schwartz O, Subbarao K, Nabel GJ. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. <span><span class="ref-journal">J Virol. </span>2004;<span class="ref-vol">78</span>:5642\xe2\x80\x935650. doi: 10.1128/JVI.78.11.5642-5650.2004.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC415834/">PMC free article</a>]</span> [<a href="/pubmed/15140961" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1128%2FJVI.78.11.5642-5650.2004" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=pH-dependent+entry+of+severe+acute+respiratory+syndrome+coronavirus+is+mediated+by+the+spike+glycoprotein+and+enhanced+by+dendritic+cell+transfer+through+DC-SIGN&amp;author=ZY+Yang&amp;author=Y+Huang&amp;author=L+Ganesh&amp;author=K+Leung&amp;author=WP+Kong&amp;volume=78&amp;publication_year=2004&amp;pages=5642-5650&amp;pmid=15140961&amp;doi=10.1128/JVI.78.11.5642-5650.2004&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR19">19. <span class="element-citation">Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. <span><span class="ref-journal">J Biol Chem. </span>2000;<span class="ref-vol">275</span>:33238\xe2\x80\x9333243. doi: 10.1074/jbc.M002615200.</span> [<a href="/pubmed/10924499" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1074%2Fjbc.M002615200" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Biol+Chem&amp;title=A+human+homolog+of+angiotensin-converting+enzyme.+Cloning+and+functional+expression+as+a+captopril-insensitive+carboxypeptidase&amp;author=SR+Tipnis&amp;author=NM+Hooper&amp;author=R+Hyde&amp;author=E+Karran&amp;author=G+Christie&amp;volume=275&amp;publication_year=2000&amp;pages=33238-33243&amp;pmid=10924499&amp;doi=10.1074/jbc.M002615200&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR20">20. <span class="element-citation">Song HC, Seo MY, Stadler K, Yoo BJ, Choo QL, Coates SR, Uematsu Y, Harada T, Greer CE, Polo JM, Pileri P, Eickmann M, Rappuoli R, Abrignani S, Houghton M, Han JH. Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein. <span><span class="ref-journal">J Virol. </span>2004;<span class="ref-vol">78</span>:10328\xe2\x80\x9310335. doi: 10.1128/JVI.78.19.10328-10335.2004.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC516425/">PMC free article</a>]</span> [<a href="/pubmed/15367599" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1128%2FJVI.78.19.10328-10335.2004" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=Synthesis+and+characterization+of+a+native,+oligomeric+form+of+recombinant+severe+acute+respiratory+syndrome+coronavirus+spike+glycoprotein&amp;author=HC+Song&amp;author=MY+Seo&amp;author=K+Stadler&amp;author=BJ+Yoo&amp;author=QL+Choo&amp;volume=78&amp;publication_year=2004&amp;pages=10328-10335&amp;pmid=15367599&amp;doi=10.1128/JVI.78.19.10328-10335.2004&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR21">21. <span class="element-citation">Keyaerts E, Vijgen L, Maes P, Neyts J, Ranst MV. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. <span><span class="ref-journal">Biochem Biophys Res Commun. </span>2004;<span class="ref-vol">323</span>:264\xe2\x80\x93268. doi: 10.1016/j.bbrc.2004.08.085.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7092815/">PMC free article</a>]</span> [<a href="/pubmed/15351731" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.bbrc.2004.08.085" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochem+Biophys+Res+Commun&amp;title=In+vitro+inhibition+of+severe+acute+respiratory+syndrome+coronavirus+by+chloroquine&amp;author=E+Keyaerts&amp;author=L+Vijgen&amp;author=P+Maes&amp;author=J+Neyts&amp;author=MV+Ranst&amp;volume=323&amp;publication_year=2004&amp;pages=264-268&amp;pmid=15351731&amp;doi=10.1016/j.bbrc.2004.08.085&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR22">22. <span class="element-citation">Thorens B, Vassalli P. Chloroquine and ammonium chloride prevent terminal glycosylation of immunoglobulins in plasma cells without affecting secretion. <span><span class="ref-journal">Nature. </span>1986;<span class="ref-vol">321</span>:618\xe2\x80\x93620. doi: 10.1038/321618a0.</span> [<a href="/pubmed/3086747" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1038%2F321618a0" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Chloroquine+and+ammonium+chloride+prevent+terminal+glycosylation+of+immunoglobulins+in+plasma+cells+without+affecting+secretion&amp;author=B+Thorens&amp;author=P+Vassalli&amp;volume=321&amp;publication_year=1986&amp;pages=618-620&amp;pmid=3086747&amp;doi=10.1038/321618a0&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR23">23. <span class="element-citation">Dille BJ, Johnson TC. Inhibition of vesicular stomatitis virus glycoprotein expression by chloroquine. <span><span class="ref-journal">J Gen Virol. </span>1982;<span class="ref-vol">62</span>:91\xe2\x80\x93103. doi: 10.1099/0022-1317-62-1-91.</span> [<a href="/pubmed/6290597" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1099%2F0022-1317-62-1-91" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Gen+Virol&amp;title=Inhibition+of+vesicular+stomatitis+virus+glycoprotein+expression+by+chloroquine&amp;author=BJ+Dille&amp;author=TC+Johnson&amp;volume=62&amp;publication_year=1982&amp;pages=91-103&amp;pmid=6290597&amp;doi=10.1099/0022-1317-62-1-91&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR24">24. <span class="element-citation">Tsai WP, Nara PL, Kung HF, Oroszlan S. Inhibition of human immunodeficiency virus infectivity by chloroquine. <span><span class="ref-journal">AIDS Res Hum Retroviruses. </span>1990;<span class="ref-vol">6</span>:481\xe2\x80\x93489. doi: 10.1089/aid.1990.6.481.</span> [<a href="/pubmed/1692728" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1089%2Faid.1990.6.481" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=AIDS+Res+Hum+Retroviruses&amp;title=Inhibition+of+human+immunodeficiency+virus+infectivity+by+chloroquine&amp;author=WP+Tsai&amp;author=PL+Nara&amp;author=HF+Kung&amp;author=S+Oroszlan&amp;volume=6&amp;publication_year=1990&amp;pages=481-489&amp;pmid=1692728&amp;doi=10.1089/aid.1990.6.481&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR25">25. <span class="element-citation">Savarino A, Lucia MB, Rastrelli E, Rutella S, Golotta C, Morra E, Tamburrini E, Perno CF, Boelaert JR, Sperber K, Cauda RC. Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. <span><span class="ref-journal">J Acquir Immune Defic Syndr. </span>2004;<span class="ref-vol">35</span>:223\xe2\x80\x93232. doi: 10.1097/00126334-200403010-00002.</span> [<a href="/pubmed/15076236" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1097%2F00126334-200403010-00002" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Acquir+Immune+Defic+Syndr&amp;title=Anti-HIV+effects+of+chloroquine:+inhibition+of+viral+particle+glycosylation+and+synergism+with+protease+inhibitors&amp;author=A+Savarino&amp;author=MB+Lucia&amp;author=E+Rastrelli&amp;author=S+Rutella&amp;author=C+Golotta&amp;volume=35&amp;publication_year=2004&amp;pages=223-232&amp;pmid=15076236&amp;doi=10.1097/00126334-200403010-00002&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR26">26. <span class="element-citation">Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. <span><span class="ref-journal">Clin Pharmacokinet. </span>1996;<span class="ref-vol">31</span>:257\xe2\x80\x93274. doi: 10.2165/00003088-199631040-00003.</span> [<a href="/pubmed/8896943" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.2165%2F00003088-199631040-00003" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Pharmacokinet&amp;title=Clinical+pharmacokinetics+and+metabolism+of+chloroquine.+Focus+on+recent+advancements&amp;author=J+Ducharme&amp;author=R+Farinotti&amp;volume=31&amp;publication_year=1996&amp;pages=257-274&amp;pmid=8896943&amp;doi=10.2165/00003088-199631040-00003&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1232869&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div></div></div></div><!--post-content--></div>\n            \n            \n        \n            \n        </div>\n        <!-- Book content -->\n    </div>\n    \n    <div id="rightcolumn" class="four_col col last">\n        <!-- Custom content above discovery portlets -->\n        <div class="col6">\n            \n        </div>\n        \n        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC1232869/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC1232869/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC1232869/pdf/12985_2005_Article_84.pdf">PDF (2.4M)</a></li> | <li><a href="#" data-citationid="PMC1232869" class="citationexporter ctxp">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1232869%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook" />\n                             Facebook\n                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1232869%2F&amp;text=Chloroquine%20is%20a%20potent%20inhibitor%20of%20SARS%20coronavirus%20infection%20and%20spread"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter" />\n                             Twitter\n                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1232869%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus" />\n                             Google+\n                        </a></li></ul></div>\n        \n        <div id="ajax-portlets" data-pmid="16115318" data-aiid="7095730" data-aid="1232869" data-iid="354810" data-domainid="3814" data-domain="phenaturepg" data-accid="PMC1232869" data-md5="0e1be4a477253c909c8f46dc493b0d77"></div>\n                \n        <!-- Custom content below discovery portlets -->\n        <div class="col7">\n            \n        </div>\n    </div>\n</div>\n\n<!-- Custom content after all -->\n<div class="col8">\n    \n</div>\n<div class="col9">\n    \n</div>\n\n<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>\n<script>\n    (function($){\n        $(\'.skiplink\').each(function(i, item){\n            var href = $($(item).attr(\'href\'));\n            href.attr(\'tabindex\', \'-1\').addClass(\'skiptarget\'); // ensure the target can receive focus\n            $(item).on(\'click\', function(event){\n                event.preventDefault();\n                $.scrollTo(href, 0, {\n                    onAfter: function(){\n                        href.focus();\n                    }\n                });\n            });\n        });\n    })(jQuery);\n</script>\n\n\n\n<div id="body-link-poppers"></div>\n                        </div>\n                        <div class="bottom">\n                            \n                            <div id="NCBIFooter_dynamic">\n    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>\n    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2020-04-17T09:09:58-04:00&amp;Snapshot=%2Fprojects%2FPMC%2FPMCViewer@4.46&amp;Host=ptpmc102&amp;ncbi_phid=8A1B33DDE99A3E9100000000042A042A&amp;ncbi_session=8A1B33DDE99AAA51_1066SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1232869%2F&amp;Db=pmc&amp;folderID=132&amp;Ncbi_App=pmc&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>\n    \n</div>\n\n                            <div class="footer" id="footer">\n    \n    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>\n    <div id="external-disclaimer" class="offscreen_noflow">\n        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.\n    </div>    \n    <div id="ncbifooter" class="contact_info">      \n        <div id="footer-contents-right">\n            <div id="nlm_thumb_logo">\n                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>\n            </div>\n            <div id="nih_thumb_logo">\n                <a href="https://www.nih.gov" title="NIH">NIH</a>\n            </div>\n            <div id="hhs_thumb_logo">\n                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>\n            </div>\n            <div id="usagov_thumb_logo">\n                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>\n            </div>         \n        </div>\n        \n        <div id="footer-contents-left">\n            <p class="address vcard">\n                <span class="url">\n                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for\n                        Biotechnology Information</a>,\n                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>\n                <span class="adr">\n                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>\n                    <span class="region">MD</span>, <span class="postal-code">20894</span>\n                    <span class="country-name">USA</span>\n                </span>\n            </p>\n            \n            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>\n        </div>\n    </div>\n    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    \n    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>\n</div>\n                        </div>\n                    </div>\n                    <!--/.page-->\n                </div>\n                <!--/.wrap-->\n            </div><!-- /.twelve_col -->\n        </div>\n        <!-- /.grid -->\n\n        <span class="PAFAppResources"></span>\n        \n        <!-- BESelector tab -->\n        \n        \n        \n        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=phenaturepg&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC1232869/&amp;ncbi_app=pmc" /></noscript>\n        \n        \n        <!-- usually for JS scripts at page bottom -->\n        <!--<component id="PageFixtures" label="styles"></component>-->\n    \n\n<!-- 8A1B33DDE99AAA51_1066SID /projects/PMC/PMCViewer@4.46 ptpmc102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->\n\n<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script></body>\n</html>'